Download PDF
Thromb Haemost 2010; 104(06): 1250-1257
DOI: 10.1160/TH10-03-0201
Animal Models
Schattauer GmbH

Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens

Lynne A. Kelly
1   Coagulation Research Laboratory, Dept of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James Hospital, Dublin, Ireland
,
John J. O’Leary
2   Dept of Pathology, Trinity Centre for Health Sciences, St. James Hospital, Dublin, Ireland
,
Dana Seidlova-Wuttke
3   Department of Endocrinology, University Medical Center, Göttingen, Göttingen, Germany
,
Wolfgang Wuttke
3   Department of Endocrinology, University Medical Center, Göttingen, Göttingen, Germany
,
Lucy A. Norris
1   Coagulation Research Laboratory, Dept of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James Hospital, Dublin, Ireland
› Author Affiliations Financial support:This study was supported by the Health Research Board of Ireland.
Further Information

Publication History

Received: 29 March 2010

Accepted after major revision: 26 July 2010

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

Summary

Recent data has shown that hormone therapy (HT) increases the risk of cardiovascular and thromboembolic disease, particularly in users of oral HT. Phytoestrogens are popular alternatives to oestrogen therapy; however, their effects on cardiovascular risk are unknown. We investigated the effect of the phytoestrogen, genistein on the expression of genes and proteins from the haemostatic system in the liver in an ovariectomised rat model. Fifty-nine virgin female Sprague-Dawley rats were fed with soy-free chow supplemented with 17β estradiol (E2) (daily uptake 0.19 or 0.75 mg/kg body weight), or genistein (daily up-take 6 or 60 mg/kg body weight), for three months and compared to soy-free control rats. Gene expression of prothrombin, factor VII, fibrinogen alpha and fibrinogen beta was increased with E2 and genistein compared to the soy-free control group (p<0.001). Genistein increased factor VII significantly more than E2 (p<0.005). Plasminogen mRNA was increased in both treatment groups compared to the soy-free control, with genistein expression significantly higher than E2 (p<0.001). Tissue plasminogen inhibitor (tPA), plasminogen activator inhibitor-1 (PAI-1) and C-reactive protein (CRP) expression were also increased in both groups relative the soy-free control. Results of protein analysis largely concurred with those of the mRNA. Oestrogen receptor β (ERβ) was undetected while oestrogen receptor α (ERα) was detected in each sample group. Genistein can increase the expression of coagulation and fibrinolytic genes. This effect was similar and in some cases higher than 17β estradiol. These results suggest that genistein may not be neutral with respect to the haemostatic system.

Keywords

Haemostasis - phytoestrogen - menopause - thrombosis
 

  • References

  • 1 European Heart Network European Cardiovascular Disease statistics. [Press publication] 2008 [cited December 1, 2009]; Available from: www.ehnheart.org
    PubMedGoogle Scholar
  • 2 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.
    CrossrefPubMedGoogle Scholar
  • 3 Hsia J, Langer RD, Manson JE. et al. Conjugated Equine Estrogens and Coronary Heart Disease: The Women’s Health Initiative. Arch Intern Med 2006; 166: 357-365.
    CrossrefPubMedGoogle Scholar
  • 4 Hulley S, Furberg C, Barrett-Connor E. et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Assoc 2002; 288: 58-64.
    CrossrefPubMedGoogle Scholar
  • 5 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605-613.
    CrossrefPubMedGoogle Scholar
  • 6 Andreana LO, Edward JK. Phytoestrogens: a review of the present state of research. Phytotherapy Res 2003; 17: 845-869.
    CrossrefPubMedGoogle Scholar
  • 7 Murkies AL, Wilcox G, Davis SR. Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab 1998; 83: 297-303.
    PubMedGoogle Scholar
  • 8 Atteritano M, Marini H, Minutoli L. et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007; 92: 3068-3075.
    CrossrefPubMedGoogle Scholar
  • 9 Sacks FM, Lichtenstein A, Van Horn L. et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-1044.
    CrossrefPubMedGoogle Scholar
  • 10 Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?. Thromb Haemost 2007; 97: 558-565.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Scarabin PY, Alhenc-Gelas M, Plu-Bureau G. et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
    CrossrefPubMedGoogle Scholar
  • 12 Rios DRA, Rodrigues ET, Cardoso APZ. et al. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women. Nutrition 2008; 24: 120-126.
    CrossrefPubMedGoogle Scholar
  • 13 Teede HJ, Dalais FS, Kotsopoulos D. et al. Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 1936-1941.
    CrossrefPubMedGoogle Scholar
  • 14 Trifiletti A, Gaudio A, Lasco A. et al. Haemostatic effects of phytoestrogen genistein in postmenopausal women. Thromb Res 2008; 123: 231-235.
    CrossrefPubMedGoogle Scholar
  • 15 Chu MC, Cushman M, Solomon R. et al. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008; 199: 526e1-7.
    CrossrefPubMedGoogle Scholar
  • 16 Kuiper GG, Lemmen JG, Carlsson B. et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263.
    CrossrefPubMedGoogle Scholar
  • 17 Dijsselbloem N, Vanden Berghe W, De Naeyer A. et al. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 2004; 68: 1171-1185.
    CrossrefPubMedGoogle Scholar
  • 18 Seidlova-Wuttke D, Hesse O, Jarry H. et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 2003; 149: 351-362.
    CrossrefPubMedGoogle Scholar
  • 19 Seidlova-Wuttke D, Jarry H, Wuttke W. Pure estrogenic effect of benzophenone-2 (BP2) but not of bisphenol A (BPA) and dibutylphtalate (DBP) in uterus, vagina and bone. Toxicology 2004; 205: 103-112.
    CrossrefPubMedGoogle Scholar
  • 20 Doerge DR, Chang HC. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 269-279.
    CrossrefPubMedGoogle Scholar
  • 21 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-1532.
    PubMedGoogle Scholar
  • 22 Lowe GD, Upton MN, Rumley A. et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey. Thromb Haemost 2001; 86: 550-556.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Hellgren M, Conard J, Norris L. et al. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009; 62: 287-293.
    CrossrefPubMedGoogle Scholar
  • 24 Ghaddar HM, Folsom AR, Aleksic N. et al. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-2821.
    CrossrefPubMedGoogle Scholar
  • 25 Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40: 1215-1220.
    CrossrefPubMedGoogle Scholar
  • 26 Soria JM, Almasy L, Souto JC. et al. A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels. Arterioscler Thromb Vasc Biol 2005; 25: 1287-1292.
    CrossrefPubMedGoogle Scholar
  • 27 Dalmon J, Laurent M, Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 1993; 13: 1183-1193.
    CrossrefPubMedGoogle Scholar
  • 28 Norris LA, Brosnan J, Bonnar J. et al. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Thromb Haemost 2008; 100: 253-260.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Stevenson JC, Oladipo A, Manassiev N. et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
    CrossrefPubMedGoogle Scholar
  • 30 Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000: 14-22.
    PubMedGoogle Scholar
  • 31 Pepys MB, Hirschfield GM, Tennent GA. et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221.
    CrossrefPubMedGoogle Scholar
  • 32 Devaraj S, Singh U, Jialal I. The Evolving Role of C-Reactive Protein in Atherothrombosis. Clin Chem 2009; 55: 229-238.
    PubMedGoogle Scholar
  • 33 Decensi A, Omodei U, Robertson C. et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-1228.
    CrossrefPubMedGoogle Scholar
  • 34 Shifren JL, Rifai N, Desindes S. et al. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008; 93: 1702-1710.
    CrossrefPubMedGoogle Scholar
  • 35 Rachon D, Suchecka-Rachon K, Hak L. et al. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006; 13: 840-845.
    PubMedGoogle Scholar
  • 36 McCarty MF. Isoflavones made simple – Genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits. Medical Hypotheses 2006; 66: 1093-1114.
    CrossrefPubMedGoogle Scholar
  • 37 Altavilla D, Crisafulli A, Marini H. et al. Cardiovascular effects of the phytoestrogen genistein. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 179-186.
    CrossrefPubMedGoogle Scholar
  • 38 Dang ZC. Dose-dependent effects of soy phyto-oestrogen genistein on adipocytes: mechanisms of action. Obes Rev 2009; 10: 342-349.
    CrossrefPubMedGoogle Scholar
  • 39 Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem 2007; 14: 2581-2589.
    CrossrefPubMedGoogle Scholar